Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 factor XI inhibition study after lower extremity revascularization in peripheral artery disease
NL-OMON61683Phase 3Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of REGN7508, amrecibart and rivaroxaban in arteriosclerosis obliterans (6 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Major thrombotic vascular events in Cohort 1 and ISTH major or clinically relevant non-major bleeding. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
REGN7508amrecibartrivaroxaban
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on NL-OMON61683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61683.